HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Harmony Biosciences Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$37.54−0.41 (-1.08%)
Close on Oct 19, 2026
- Market cap
- $2.21B
- P/E (TTM)
- 12.1
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
93.0%
54M of 58M shares
Institutional holders
327
53 new, 33 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 13 sales
Net sold $5.95M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 6,525,663 | 11.30% | 13G (passive) amendment | Jun 30, 2026 |
| Marshman Fund Trust II | 6,051,120 | 10.60% | 13G (passive) amendment | Dec 31, 2024 |
| FMR LLC | 3,846,972 | 6.70% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson | 3,112,812 | 5.40% | 13G (passive) amendment | Dec 31, 2025 |
| Vanguard Portfolio Management | 2,943,383 | 5.08% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HRMY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,101,965 | 12.20% | $258.58M | +31,930 | 0.00% |
| FMR LLC | 3,574,115 | 6.14% | $130.13M | +416,476 | 0.01% |
| Vanguard Portfolio Management LLC | 2,880,489 | 4.95% | $104.88M | +166,136 | 0.00% |
| American Century Companies Inc | 2,539,512 | 4.36% | $92.46M | +434,333 | 0.04% |
| Dimensional Fund Advisors LP | 2,393,588 | 4.11% | $87.14M | +317,078 | 0.02% |
| Vanguard Capital Management LLC | 2,105,053 | 3.61% | $76.64M | +2,738 | 0.00% |
| Lsv Asset Management | 2,061,242 | 3.54% | $75.05K | +36,099 | 0.14% |
| State Street Corp | 1,859,322 | 3.19% | $67.70M | +74,960 | 0.00% |
| Armistice Capital, LLC | 1,564,000 | 2.69% | $56.95M | −60,000 | 0.70% |
| Geode Capital Management, LLC | 1,442,649 | 2.48% | $52.53M | +119,929 | 0.00% |
| Arrowstreet Capital, Limited Partnership | 1,312,550 | 2.25% | $47.79M | −69,563 | 0.02% |
| Renaissance Technologies LLC | 1,195,371 | 2.05% | $43.52M | +118,000 | 0.06% |
| Two Sigma Investments, LP | 959,136 | 1.65% | $34.92M | +225,693 | 0.03% |
| Aqr Capital Management LLC | 934,326 | 1.60% | $34.02M | +218,080 | 0.01% |
| SG Americas Securities, LLC | 882,720 | 1.52% | $32.14K | −1,135,454 | 0.02% |
| Valor Management LLC | 818,013 | 1.40% | $29.78M | +700,883 | 0.03% |
| Morgan Stanley | 733,684 | 1.26% | $26.71M | −297,334 | 0.00% |
| UBS Group AG | 602,990 | 1.04% | $21.95M | +154,999 | 0.00% |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 551,075 | 0.95% | $20.06M | −16,040 | 0.02% |
| Invesco Ltd. | 528,520 | 0.91% | $19.24M | −99,727 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 327 | 54M | 93.0% | 53 / 131 | 107 / 33 | 6M | 8M |
| Q1 2026 | 311 | 56M | 96.1% | 44 / 131 | 98 / 51 | 16M | 6M |
| Q4 2025 | 325 | 50M | 86.1% | 60 / 121 | 111 / 30 | 8M | 5M |
| Q3 2025 | 297 | 48M | 81.8% | 45 / 116 | 88 / 26 | 6M | 9M |
| Q2 2025 | 279 | 51M | 88.0% | 39 / 126 | 71 / 31 | 6M | 5M |
| Q1 2025 | 272 | 50M | 86.4% | 42 / 100 | 87 / 16 | 5M | 7M |
| Q4 2024 | 247 | 53M | 90.6% | 39 / 128 | 49 / 25 | 11M | 9M |
| Q3 2024 | 234 | 50M | 86.5% | 39 / 72 | 87 / 22 | 9M | 3M |
| Q2 2024 | 219 | 50M | 86.4% | 35 / 76 | 73 / 21 | 3M | 4M |
| Q1 2024 | 207 | 51M | 87.2% | 27 / 64 | 80 / 40 | 5M | 3M |
| Q4 2023 | 221 | 49M | 84.4% | 55 / 62 | 78 / 35 | 7M | 7M |
| Q3 2023 | 204 | 49M | 84.9% | 32 / 86 | 57 / 39 | 2M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of HRMY | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2,407,170 | 4.13% | $87.65M | 0.08% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 2,032,950 | 3.49% | $64.22M | 0.24% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,556,602 | 2.67% | $56.68M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,159,605 | 1.99% | $42.22M | 0.05% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,127,559 | 1.94% | $41.05M | 0.02% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 1,007,798 | 1.73% | $31.84M | 0.03% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 653,920 | 1.12% | $23.81M | 0.05% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 493,988 | 0.85% | $17.41M | 0.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 461,568 | 0.79% | $16.81M | 0.02% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 457,483 | 0.79% | $16.66M | 0.29% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 417,018 | 0.72% | $15.18M | 0.10% | Jun 30, 2026 |
| Invesco Pharmaceuticals ETF | 410,448 | 0.70% | $14.46M | 3.06% | Jul 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 366,197 | 0.63% | $13.33M | 0.08% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 360,552 | 0.62% | $13.13M | 0.16% | Jun 30, 2026 |
| Pacer US Small Cap Cash Cows 100 ETF | 340,511 | 0.58% | $12.00M | 0.33% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeffrey M. Dayno | PRESIDENT, CEO, Director | 13,000 | 0.02% | Jan 26, 2026 |
| Kumar Budur | CHIEF MEDICAL OFFICER | 48,967 | 0.08% | Sep 18, 2026 |
| Stephen M. Mollichella | INT PRINCIAL FINANCIAL OFFICER | 2,506 | 0.00% | Jul 22, 2026 |
| Glenn Reicin | CHIEF FINANCIAL OFFICER | – | – | May 18, 2026 |
| Adam H. Zaeske | CHIEF COMMERCIAL OFFICER | 4,327 | 0.01% | Apr 9, 2026 |
| Peter Anastasiou | CHIEF OPERATING OFFICER | – | – | Apr 6, 2026 |
| Sandip Kapadia | CHIEF FINANCIAL OFFICER | 24,521 | 0.04% | Jan 28, 2026 |
| Andrew Serafin | CHIEF STRATEGY OFFICER | 1,474 | 0.00% | Jan 26, 2026 |
| Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | 500 | 0.00% | Mar 5, 2025 |
| R. Mark Graf | Director | – | – | May 18, 2026 |
| Geno J. Germano | Director | – | – | May 18, 2026 |
| Linda M. Szyper | Director | – | – | May 18, 2026 |
| Ron M. Philip | Director | – | – | May 18, 2026 |
| Juan A. Sabater | Director | 29,497 | 0.05% | May 18, 2026 |
| Gary Sender | Director | – | – | May 18, 2026 |
| Troy A. Ignelzi | Director | – | – | Apr 6, 2026 |
| Antonio J. Gracias | Director, 10% owner | 845,336 | 1.45% | Sep 2, 2025 |
| Equity Partners Iv L.P. Valor | 10% owner | – | – | Sep 2, 2025 |
| Valor IV Pharma Holdings, LLC | 10% owner | – | – | Sep 2, 2025 |
| Management L.P. Valor | 10% owner | – | – | Sep 2, 2025 |
| Equity Partners Iv-A L.P. Valor | 10% owner | – | – | Sep 2, 2025 |
| Equity Partners Iv-B L.P. Valor | 10% owner | 6,618,033 | 11.36% | Sep 2, 2025 |
| Equity Capital IV LLC Valor | 10% owner | – | – | Sep 2, 2025 |
| Equity Associates IV L.P. Valor | 10% owner | 10,984,981 | 18.86% | Sep 2, 2025 |
| Fund Trust Marshman II | 10% owner | 6,051,120 | 10.39% | Nov 5, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 18, 2026 | Option exercise | +25,446 | $30.27 | $770.25K | 48,967 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 18, 2026 | Sale(10b5-1 plan) | −35,852 | $43.05 | $1.54M | 13,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 18, 2026 | Option exercise | +10,406 | $30.69 | $319.36K | 23,521 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −800 | $43.00 | $34.40K | 13,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 17, 2026 | Option exercise | +400 | $30.27 | $12.11K | 13,915 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 17, 2026 | Option exercise | +400 | $30.69 | $12.28K | 13,515 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 16, 2026 | Option exercise | +900 | $30.69 | $27.62K | 14,015 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 16, 2026 | Option exercise | +900 | $30.27 | $27.24K | 14,915 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 16, 2026 | Sale(10b5-1 plan) | −1,800 | $43.01 | $77.42K | 13,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 8, 2026 | Sale(10b5-1 plan) | −4,500 | $42.25 | $190.13K | 14,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 8, 2026 | Sale(10b5-1 plan) | −1,000 | $42.79 | $42.79K | 13,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 8, 2026 | Option exercise | +12,200 | $30.69 | $374.42K | 25,315 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 8, 2026 | Sale(10b5-1 plan) | −22,954 | $43.10 | $989.32K | 13,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 8, 2026 | Option exercise | +10,754 | $30.27 | $325.52K | 36,069 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 4, 2026 | Sale(10b5-1 plan) | −5,500 | $41.98 | $230.89K | 18,615 |
| Kumar Budur CHIEF MEDICAL OFFICER | May 1, 2026 | Option exercise | +18,750 | – | – | 32,997 |
| Kumar Budur CHIEF MEDICAL OFFICER | May 1, 2026 | Tax withholding | −8,882 | $31.83 | $282.71K | 24,115 |
| Adam H. Zaeske CHIEF COMMERCIAL OFFICER | Apr 7, 2026 | Tax withholding | −3,173 | $27.62 | $87.64K | 4,327 |
| Adam H. Zaeske CHIEF COMMERCIAL OFFICER | Apr 7, 2026 | Option exercise | +7,500 | – | – | 7,500 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 26, 2026 | Sale(10b5-1 plan) | −3,746 | $37.15 | $139.16K | 24,521 |
| Kumar Budur CHIEF MEDICAL OFFICER | Jan 25, 2026 | Option exercise | +2,662 | – | – | 2,662 |
| Kumar Budur CHIEF MEDICAL OFFICER | Jan 25, 2026 | Tax withholding | −1,372 | $36.82 | $50.52K | 1,290 |
| Andrew Serafin CHIEF STRATEGY OFFICER | Jan 25, 2026 | Tax withholding | −1,126 | $36.82 | $41.46K | 1,474 |
| Andrew Serafin CHIEF STRATEGY OFFICER | Jan 25, 2026 | Option exercise | +2,600 | – | – | 2,600 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 25, 2026 | Tax withholding | −2,553 | $36.82 | $94.00K | 2,172 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 25, 2026 | Option exercise | +4,725 | – | – | 4,725 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 25, 2026 | Option exercise | +13,000 | – | – | 13,000 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 25, 2026 | Tax withholding | −5,654 | $36.82 | $208.18K | 7,346 |
| Kumar Budur CHIEF MEDICAL OFFICER | Jan 24, 2026 | Tax withholding | −1,153 | $36.82 | $42.45K | 1,035 |
| Kumar Budur CHIEF MEDICAL OFFICER | Jan 24, 2026 | Option exercise | +2,188 | – | – | 2,188 |
| Andrew Serafin CHIEF STRATEGY OFFICER | Jan 24, 2026 | Tax withholding | −1,116 | $36.82 | $41.09K | 1,384 |
| Andrew Serafin CHIEF STRATEGY OFFICER | Jan 24, 2026 | Option exercise | +2,500 | – | – | 2,500 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 24, 2026 | Tax withholding | −2,239 | $36.82 | $82.44K | 1,574 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 24, 2026 | Option exercise | +3,813 | – | – | 3,813 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 24, 2026 | Tax withholding | −4,785 | $36.82 | $176.18K | 5,715 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 24, 2026 | Option exercise | +10,500 | – | – | 10,500 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 15, 2026 | Sale(10b5-1 plan) | −20,961 | $35.92 | $752.92K | 0 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Dec 12, 2025 | Option exercise | +20,000 | $8.22 | $164.40K | 20,000 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Dec 12, 2025 | Sale(10b5-1 plan) | −20,000 | $40.11 | $802.20K | 0 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Dec 12, 2025 | Sale(10b5-1 plan) | −5,933 | $40.11 | $237.97K | 0 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Dec 5, 2025 | Sale(10b5-1 plan) | −20,000 | $39.54 | $790.80K | 0 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Dec 5, 2025 | Option exercise | +20,000 | $29.03 | $580.60K | 20,000 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Nov 21, 2025 | Sale(10b5-1 plan) | −3,427 | $35.00 | $119.95K | 0 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Sep 30, 2025 | Tax withholding | −24,039 | $27.56 | $662.51K | 20,961 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Sep 30, 2025 | Option exercise | +45,000 | – | – | 45,000 |
| Juan A. Sabater Director, 10% owner | Aug 28, 2025 | Other | −6,618,033 | – | – | 0 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Aug 15, 2025 | Sale(10b5-1 plan) | −21,573 | $36.50 | $787.41K | 0 |
| Kumar Budur CHIEF MEDICAL OFFICER | May 1, 2025 | Option exercise | +18,750 | – | – | 18,750 |
| Kumar Budur CHIEF MEDICAL OFFICER | May 1, 2025 | Tax withholding | −8,869 | $29.86 | $264.83K | 9,881 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Apr 1, 2025 | Sale(10b5-1 plan) | −740 | $33.12 | $24.51K | 0 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Apr 1, 2025 | Sale(10b5-1 plan) | −6,247 | $32.48 | $202.90K | 740 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Mar 29, 2025 | Option exercise | +15,000 | – | – | 15,000 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Mar 29, 2025 | Tax withholding | −8,014 | $33.19 | $265.98K | 6,986 |
| Jeffrey Dierks CHIEF COMMERCIAL OFFICER | Mar 3, 2025 | Sale(10b5-1 plan) | −4,369 | $32.61 | $142.47K | 500 |
| Jeffrey Dierks CHIEF COMMERCIAL OFFICER | Mar 3, 2025 | Sale(10b5-1 plan) | −500 | $33.23 | $16.62K | 0 |
| Jeffrey Dierks CHIEF COMMERCIAL OFFICER | Mar 3, 2025 | Option exercise | +4,869 | $8.22 | $40.02K | 4,869 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 27, 2025 | Sale(10b5-1 plan) | −1,775 | $38.05 | $67.54K | 0 |
| Jeffrey Dierks CHIEF COMMERCIAL OFFICER | Jan 27, 2025 | Sale(10b5-1 plan) | −1,629 | $38.02 | $61.93K | 0 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 24, 2025 | Option exercise | +10,500 | – | – | 10,500 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 24, 2025 | Tax withholding | −4,567 | $38.01 | $173.59K | 5,933 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Budur Kumar Officer | Sep 18, 2026 | 35,852 | $1.53M | Sep 18, 2026 | Exercise of Stock Options |
| Budur Kumar Officer | Sep 17, 2026 | 800 | $33.77K | Sep 17, 2026 | Exercise of Stock Options |
| Budur Kumar Officer | Sep 16, 2026 | 1,800 | $75.91K | Sep 16, 2026 | Exercise of Stock Options |
| Budur Kumar Officer | Sep 8, 2026 | 28,454 | $1.20M | Sep 8, 2026 | Restricted Stock Units |
| Budur Kumar Officer | Sep 4, 2026 | 5,500 | $230.23K | Sep 4, 2026 | Restricted Stock Units |
| Iv Pharma Holdings Llc Valor Director | Aug 7, 2026 | 700,883 | $26.56M | Aug 7, 2026 | Private Acquisition from Issuer/Affiliate |
| Kapadia Sandip Former Officer | Jul 2, 2026 | 25,000 | $924.01K | Jul 2, 2026 | Exercise of Options Under a Registered Plan |
| Kapadia Sandip Former Officer | Jun 30, 2026 | 50,000 | $1.80M | Jun 30, 2026 | Exercise of Options Under a Registered Plan |
| Kapadia Sandip Former Officer | Jun 26, 2026 | 45,594 | $1.61M | Jun 26, 2026 | Exercise of Options Under a Registered Plan |
| Kapadia Sandip Former Officer | Jun 24, 2026 | 4,406 | $154.30K | Jun 24, 2026 | Exercise of Options Under a Registered Plan |
| Kapadia Sandip Former Officer | Jun 9, 2026 | 27,960 | $943.26K | Jun 9, 2026 | Exercise of Options Under a Registered Plan |
| Kapadia Sandip Former Officer | Jun 5, 2026 | 2,101 | $69.50K | Jun 5, 2026 | Exercise of Options Under a Registered Plan |
| Kapadia Sandip Former Officer | Jun 4, 2026 | 7,064 | $233.23K | Jun 4, 2026 | Exercise of Options Under a Registered Plan |
| Kapadia Sandip Former Officer | May 8, 2026 | 45,481 | $1.43M | May 8, 2026 | Restricted stock vesting under a registered plan |
| Kapadia Sandip Officer | Jan 26, 2026 | 3,746 | $137.93K | Jan 26, 2026 | Restricted Stock Units |